Showing 3951-3960 of 5623 results for "".
- Nidek Launches Cube Alpha Ophthalmic Surgical Systemhttps://modernod.com/news/nidek-launches-cube-a-ophthalmic-surgical-system/2481390/Nidek has announced the launch of the Cube α ophthalmic surgical system, which is designed to incorporate new ultrasound technology to deliver more powerful and effective phacoemulsification. According to Nidek, the Cube α incorporates Gyro torsional technolog
- Clearside Biomedical Announces Leadership Changeshttps://modernod.com/news/clearside-biomedical-announces-leadership-changes/2481386/Clearside Biomedical announced that its Chief Medical Officer and Chief Development Officer, Thomas A. Ciulla, MD, will transition to the role of Chief Medical Advisor-Retina for Clearside and step down from his full-time position, effective February 17, 2023. In his new advisory capacity, Dr. Ci
- Tracey Technologies Launches iTrace Prime Upgraded Software for iTrace Aberrometerhttps://modernod.com/news/tracey-technologies-launches-itrace-prime-upgraded-software-for-itrace-aberrometer/2481384/Tracey Technologies announced the release of iTrace Prime, an upgraded software for the iTrace Ray Tracing aberrometer and corneal topographer. This new software version (7.0) adds new features that improve the range of information able to be gathered from a single device, accordi
- Nidek and Hoya Vision Care Enter Global Partnershiphttps://modernod.com/news/nidek-and-hoya-vision-care-enter-global-partnership/2481381/Nidek has announced a partnership with Hoya Vision Care that would allow Hoya's customers access to Nidek's optical products, services and instruments through both local distributors. Financial terms of the deal were not disclosed. The aim of the partnership
- Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX in Wet AMDhttps://modernod.com/news/clearside-biomedical-announces-positive-6-month-results-from-oasis-extension-study-with-suprachoroidal-cls-ax-in-wet-amd/2481380/Clearside Biomedical announced positive results from the extension study of its OASIS phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) administered by suprachoroidal injection via Clearside’s SCS Microinjector in wet age-related macular degeneration (AMD) parti
- Nidek Launches the AL-Scan M Optical Biometerhttps://modernod.com/news/nidek-launches-the-al-scan-m-optical-biometer/2481376/Nidek has announced the launch of the AL-Scan M Optical Biometer and the MV-1 Myopia Viewer software. The AL-Scan M incorporates 3D auto tracking and auto shot functions, designed for easy operation and quick measurement similar to an auto refractometer. Nidek says the features&nbs
- TFS HealthScience Acquires Appletree CI Group, Expanding Presence in Ophthalmologyhttps://modernod.com/news/tfs-healthscience-acquires-appletree-ci-group-expanding-into-ophthalmology/2481363/Contract research organization TFS HealthScience announced it has acquired Appletree CI Group, a CRO and global regulatory affairs service provider. Terms of the deal were not disclosed. The deal enhances TFS HealthScience's presence in the fields of op
- Three-Month Efficacy/Safety Data of SING IMT for AMD Publishedhttps://modernod.com/news/three-month-efficacysafety-data-of-sing-imt-for-amd-published/2481362/The first and largest single-surgeon case series to describe the short-term (3 months) safety and efficacy outcomes of the Smaller-Incision New-Generation Implantable Miniature Telescope (SING IMT) in patients with severe to profound bilateral central vision impairment due to advanced A
- Harrow Completes Acquisition of US Rights to Five Branded Ophthalmic Drugshttps://modernod.com/news/harrow-closes-acquisition-of-us-rights-to-ilevro-nevanac-vigamox-maxidex-and-triesence-and-will-begin-receiving-net-profit-payments-for-acquired-products/2481361/Harrow announced the closing of its previously announced acquisition with Novartis of the exclusive US commercial rights to five branded ophthalmic products: Ilevro, Nevanac, Vigamox, Maxidex, and Triesence. In December, Harrow announced it had 
- CXL Ophthalmics Appoints Jonathan Talamo, MD, as Chair of the Boardhttps://modernod.com/news/cxl-ophthalmics-appoints-jonathan-talamo-md-as-chair-of-the-board/2481355/CXL Ophthalmics announced that Jonathan Talamo, MD, has been appointed as its new Chair of the Board of Directors. Dr. Talamo has served as a Board member for the company since 2020. CXLO is developing a minimally-invasive treatment for ectatic corneal disease. The company's Ep